PMC8263906_01
Scans at baseline, first evaluation (+6 weeks), and second evaluation (+15 weeks) in a SS18-POU5F1 sarcoma patient with multiple lymph node metastases (LNM) who accepted immune checkpoint inhibitor, angiogenesis inhibitor, chemotherapy and radiotherapy.
fonc-11-666946-g001.jpg
PMC8263906_01_fonc-11-666946-g001.jpg
f1
A contrast-enhanced total-body computed tomography (CT) scan (head to foot) revealed pelvic, mediastinal and bilateral subclavian lymphadenopathy ( Figure 1 , Baseline). However, unfortunately, a progressive disease was confirmed in the abdominal regions outside the radiation fields ( Figure 1 , 1st evaluation). A total-body CT scan (head to foot) showed progression of the left inguinal, pelvic, mediastinal and bilateral subclavian lymph node metastases ( Figure 1 , 2nd evaluation).